| Mallory Lynn Oliva, | |
|
224 High St, Cumberland, RI 02864-7904 | |
| (774) 955-7483 | |
| Not Available |
| Full Name | Mallory Lynn Oliva |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 224 High St, Cumberland, Rhode Island |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457931958 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 93962 (Massachusetts) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mallory Lynn Oliva, 224 High St, Cumberland, RI 02864-7904 Ph: (774) 955-7483 | Mallory Lynn Oliva, 224 High St, Cumberland, RI 02864-7904 Ph: (774) 955-7483 |
News Archive
Last week's announcement of final guidelines for medical providers and EHR vendors has officially kicked off the national health IT transition. As part of the 2009 economic stimulus plan (ARRA), billions have been earmarked to incentivize the Meaningful Use of Electronic Health Record (EHR) technology in the US. Eligible medical providers can each qualify for $44,000+ in stimulus incentives starting in 2011, incentives that will drive health IT adoption and could bring as much as $4 billion to individual states.
Optimer Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2010. Optimer reported a net loss for the third quarter of 2010 of $11.8 million, or $0.30 per share, which was in line with the Company's expectations. This compares to a net loss for the third quarter of 2009 of $9.4 million, or $0.28 per share. The increase in net loss was primarily due to an increase in research and development and marketing expenses.
HealthLeaders-InterStudy and Fingertip Formulary find that over the next five years, a greater percentage of health plans will transition orally delivered oncology drugs from a copayment structure to a reimbursement model that incorporates a coinsurance payment, thereby shifting more costs onto patients. Copayments represent a set dollar amount associated with a pharmacy benefit while coinsurance represents a percentage of cost that must be paid by the beneficiary.
The National Academy of Sciences and the National Academy of Medicine are launching a major initiative to guide decision making about controversial new research involving human gene editing. Human gene-editing technologies, such as CRISPR-Cas9, may lead to promising new treatments for disease.
› Verified 5 days ago